Table 2.
The top ten upregulated and top ten downregulated miRNAs in MV+ patients compared to MV− patients in the discovery sample using NGS.
Chr | Start | End | logFC MV+ vs MV− | p value MV+ vs MV− | |
---|---|---|---|---|---|
Downregulated miRNAs | |||||
hsa-miR-144-3p | chr17 | 28,861,548 | 28,861,567 | − 1.952 | 0.011 |
hsa-miR-15a-3p | chr13 | 50,049,130 | 50,049,151 | − 1.941 | 0.003 |
hsa-miR-374a-3p | chrX | 74,287,295 | 74,287,316 | − 1.886 | 0.002 |
hsa-miR-181c-5p | chr19 | 13,874,725 | 13,874,746 | − 1.849 | 0.001 |
hsa-miR-374a-5p | chrX | 74,287,325 | 74,287,346 | − 1.831 | 0.004 |
hsa-miR-1277-5p | chrX | 118,386,401 | 118,386,424 | − 1.795 | 0.004 |
hsa-miR-369-3p | chr14 | 101,065,641 | 101,065,661 | − 1.783 | 0.005 |
hsa-miR-146a-3p | chr5 | 160,485,408 | 160,485,429 | − 1.761 | 0.011 |
hsa-miR-556-3p | chr1 | 162,342,600 | 162,342,621 | − 1.746 | 0.007 |
hsa-miR-16-1-3p | chr13 | 50,048,985 | 50,049,006 | − 1.716 | 0.009 |
Upregulated miRNAs | |||||
hsa-miR-193b-5p | chr16 | 14,303,980 | 14,304,001 | 2.650 | 0.001 |
hsa-miR-4669 | chr9 | 134,379,449 | 134,379,470 | 2.512 | 0.009 |
hsa-miR-193a-5p | chr17 | 31,560,016 | 31,560,037 | 2.168 | 0.0001 |
hsa-miR-4697-3p | chr11 | 133,898,506 | 133,898,529 | 1.957 | 0.048 |
hsa-miR-4516 | chr16 | 2,133,120 | 2,133,136 | 1.955 | 0.002 |
hsa-miR-1228-3p | chr12 | 57,194,555 | 57,194,574 | 1.932 | 0.007 |
hsa-miR-3182 | chr16 | 83,508,349 | 83,508,365 | 1.862 | 0.0005 |
hsa-miR-150-3p | chr19 | 49,500,797 | 49,500,818 | 1.826 | 0.005 |
hsa-miR-885-3p | chr3 | 10,394,499 | 10,394,520 | 1.753 | 0.019 |
hsa-miR-34c-3p | chr11 | 111,513,484 | 111,513,505 | 1.690 | 0.018 |
miRNA name: Annotations related to the gene (miRNA) according to miRBase v22.1, genome version GRCh38. p value obtained with the moderated t-test.
Chr chromosome, logFC log2 fold change, MV mechanical ventilation requirement.